Macozinone (PBTZ-169) is a tuberculosis drug candidate that has demonstrated high potency against drug-susceptible and drug-resistant TB in preclinical studies. Macozinone has additive effects with many TB therapeutic agents, both marketed and in development, and has synergic effects with bedaquiline and clofazimine in preclinical models. Macozinone is in phase II of clinical development, and pre-clinical work is ongoing for a long-acting injectable version, in collaboration with MedinCell.
Primary patents on macozinone have been granted in key countries of manufacture such as India, China and South Africa and are expected to expire in 2031. Secondary patents may be filed.

Acronyms & abbreviations list